Noetik, a San Francisco, CA-based AI drug discovery company, raised $14M in Seed funding.
The round was led by DCVC, with participation from Zetta Venture Partners, 11.2 Capital, Catalio Capital Management, Epic Ventures, Intermountain Ventures, North South Ventures, Chau Khuong and CJNV BioVentures, Enveda Founder and CEO, Viswa Colluru and Hummingbird Nomads Fund, and Recursion CEO & CFO, Chris Gibson and Michael Secora.
The company intends to use the funds to support it internal data generation efforts and the continued development of transformer-based machine learning methods, as well as to expand Its team in machine learning, computational biology, and cancer immunology.
Led by Ron Alfa, M.D., Ph.D. and CEO, and Jacob Rinaldi, Ph.D., CSO, Noetik is an AI-native biotechnology company that has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to tackle fundamental problems in cancer immunology. In less than 12 months of operations, the company has generated human data across a data stack that includes genomics, transcriptomics, and proteomics to enable the development of foundation models for cell and tissue biology.
Noetik’s founding leadership team includes Lacey Padron, Ph.D., Chief Technical Officer, who was previously VP Informatics at the Parker Institute for Cancer Immunotherapy. At the Parker Institute, Padron focused on using integrated multiomic data analysis to uncover biomarkers, mechanisms of action, and novel therapies from cancer immunotherapy patient data. She also led the development of a best-in-class data platform to store, integrate, and analyze data from 20+ molecular data types with detailed clinical outcomes and annotation.
FinSMEs
07/09/2023